11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02519049|
Recruitment Status : Unknown
Verified November 2016 by Istituto Clinico Humanitas.
Recruitment status was: Recruiting
First Posted : August 10, 2015
Last Update Posted : November 21, 2016
|Condition or disease||Intervention/treatment|
|Mesothelioma, Malignant||Other: No intervention|
This is a single-center, open-label study, lasting 36 months including an estimated period of 24 months for the enrollment and max 12 months of follow-up. All patients affected by MPM and referred to our Institution eligible for therapeutic pleurodesis and subsequent platinum- and pemetrexed-based chemotherapy will be enrolled. In all cases patients will be investigated with 11C-Methionine PET/CT and 18F-FDG PET/CT before talc pleurodesis, one week after and at the end of three cycles of chemotherapy.
A minimum number of 20 patients will be considered for the analysis.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Diagnostic and Prognostic Role of 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) and Candidate to Pleurodesis|
|Study Start Date :||September 2014|
|Estimated Primary Completion Date :||September 2017|
|Estimated Study Completion Date :||November 2017|
- Other: No intervention
This is an observational study
- Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing talc pleurodesis [ Time Frame: Change from Baseline in SUVmax up to 1 week after talc pleurodesis. ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02519049
|Contact: Egesta Lopci, MD||+39 email@example.com|
|Contact: Paolo Zucali, MD||+39 firstname.lastname@example.org|
|Istituto Clinico Humanitas||Recruiting|
|Rozzano, Milano, Italy, 20089|
|Contact: Egesta Lopci, MD +39 0282247542|
|Principal Investigator:||Egesta Lopci, MD||Humanitas Clinical and Research Hospital|